Creb Binding Protein
Background
Section titled “Background”The CREBBPgene, encoding the CREB-binding protein (CBP), is a critical transcriptional coactivator with diverse roles in eukaryotic gene regulation. As a highly conserved nuclear protein, CBP plays a central role in numerous cellular processes, including cell growth, differentiation, apoptosis, and development. Its broad involvement stems from its ability to integrate signals from various pathways and modulate gene expression.
Biological Basis
Section titled “Biological Basis”Biologically, CREBBP functions primarily as a histone acetyltransferase (HAT), an enzyme that adds acetyl groups to lysine residues on histone proteins. This acetylation relaxes chromatin structure, making DNA more accessible to transcription machinery and thereby facilitating gene transcription. Beyond its HAT activity, CREBBP also serves as a scaffold, interacting with a vast array of transcription factors, including CREB, NF-κB, and members of the CAAT enhancer binding protein (C/EBP) family. Through these interactions, CREBBP enhances the transcriptional activity of its binding partners.
Given its role in coactivating key transcription factors, CREBBPcan influence inflammatory responses. For instance, C-reactive protein (CRP), a prominent acute-phase reactant, has its synthesis largely under the transcriptional control of cytokines such as interleukin-6 (IL-6) and interleukin-1 beta (IL-1b), and transcription-factor complexes including NF-kB and C/EBPbeta [1]. [2] An HNF-1a binding site in the CRP gene promoter overlaps with an NFkB binding site, highlighting the intricate regulatory network involved in CRP synthesis. [2] Polymorphisms within genes like HNF1A have been strongly associated with variations in plasma CRP levels, demonstrating the significant genetic component in regulating this inflammatory marker [2]. [3] Other loci, including LEPR, IL6R, and GCKR, also show associations with plasma CRP. [3]
Clinical Relevance
Section titled “Clinical Relevance”Dysregulation or mutations in CREBBPare implicated in various human diseases, notably Rubinstein-Taybi syndrome, a developmental disorder characterized by intellectual disability and physical abnormalities. Its role in chromatin remodeling also links it to different types of cancer. From an inflammatory perspective, high basal levels ofCRPare known to predict future cardiovascular disease and metabolic abnormalities in otherwise healthy adults[2]. [3] The genetic variations influencing CRP levels, such as those found in HNF1A, contribute to the individual susceptibility to these conditions [2]. [3] Understanding the broader genetic landscape, including coactivators like CREBBP, that impacts inflammatory pathways is therefore crucial for assessing disease risk.
Social Importance
Section titled “Social Importance”The social importance of studying genes like CREBBP and their indirect or direct effects on inflammatory markers such as CRPlies in their potential to inform public health strategies. Cardiovascular disease and metabolic syndrome are leading causes of morbidity and mortality worldwide. By elucidating the genetic and molecular underpinnings of inflammation and its biomarkers, researchers can identify individuals at higher risk, develop more precise diagnostic tools, and pave the way for targeted therapeutic interventions. This mechanistic understanding supports the shift towards personalized medicine, offering the potential for earlier prevention and more effective management of widespread chronic diseases.
Limitations
Section titled “Limitations”Study Design and Statistical Constraints
Section titled “Study Design and Statistical Constraints”The moderate size of the study cohorts often limits statistical power, increasing the susceptibility to false negative findings and making it challenging to detect genetic associations with modest effect sizes.[4] Conversely, the inherent complexity of genome-wide association studies (GWAS), involving numerous statistical comparisons, raises the risk of false positive associations if stringent adjustments for multiple testing are not applied. [4] Many initial associations may not achieve the rigorous genome-wide significance thresholds after conservative corrections, underscoring the critical need for replication in independent cohorts to validate findings and confirm true genetic links. [4] Furthermore, discrepancies in findings can arise from the use of different analytical methodologies, such as family-based versus population-based tests, which can lead to divergent results and complicate the overall interpretation of genetic signals. [5]
Generalizability and Phenotypic Characterization
Section titled “Generalizability and Phenotypic Characterization”A significant limitation in many genetic studies is the composition of the research cohorts, which are frequently biased towards individuals of white European descent and often skewed towards middle-aged to elderly populations. [4] This demographic homogeneity restricts the generalizability of findings to younger individuals or to diverse ethnic and racial groups, potentially overlooking population-specific genetic effects. Additionally, biases such as survival bias may be introduced if DNA samples are collected at later life stages, as this may exclude individuals who did not survive to those examination points. [4] Phenotypic characterization also presents challenges, as some biomarkers may serve as proxy measures for broader physiological states or require complex statistical transformations to approximate normality. [6] These methodological choices, while sometimes necessary, can influence the precision of genetic association estimates and may lead to missing important bivariate associations.
Genomic Coverage and Unexplained Genetic Variation
Section titled “Genomic Coverage and Unexplained Genetic Variation”Many GWAS platforms employ a subset of all known single nucleotide polymorphisms (SNPs), which can result in incomplete genomic coverage. This limitation means that specific genetic variants, particularly within or near candidate genes, may not be adequately tagged or genotyped, leading to missed associations and an incomplete understanding of genetic influences on traits.[7] Such gaps in coverage can hinder the comprehensive study of candidate genes and the discovery of novel genetic loci. Moreover, to mitigate the multiple testing burden, some studies opt for sex-pooled analyses, which can inadvertently obscure important sex-specific genetic associations that might only manifest in males or females. [7] These limitations collectively contribute to the phenomenon of missing heritability, where a substantial portion of the genetic variation underlying complex traits remains unexplained by identified genetic variants.
Variants
Section titled “Variants”The genetic landscape influencing various biological processes includes several variants and their associated genes, which can impact cellular function and potentially interact with pathways involving CREB binding protein. For instance, the pseudogenesINTS6P1 and GCSHP1, alongside the variant rs62359722 , represent genetic elements that may subtly influence cellular processes. Pseudogenes, though often non-coding, can play regulatory roles by interfering with the expression of their functional counterparts or by generating non-coding RNAs that modulate gene activity. A single nucleotide polymorphism likers62359722 could alter the stability or regulatory capacity of these pseudogenes, potentially affecting the expression levels of other genes involved in cellular signaling or transcriptional control. [4]Such modulations could indirectly impact the activity of CREB binding protein (CBP), a crucial coactivator involved in diverse cellular functions, including neuronal plasticity and metabolic regulation.[4] Alterations in these pseudogenes or their associated variant might lead to subtle shifts in gene expression patterns that converge on CREB/CBP-mediated pathways, affecting cellular responses to stress or developmental cues.
Variants rs62358361 and rs835219 are associated with the C9 gene, which encodes Complement Component 9, a vital protein in the immune system’s complement cascade. C9 is essential for forming the membrane attack complex, a structure that helps eliminate pathogens by creating pores in their cell membranes. Genetic variations within C9 can affect the efficiency of this immune response, potentially influencing susceptibility to inflammatory conditions or autoimmune disorders. [4] Given that inflammation and immune signaling pathways frequently engage and modulate the activity of CREB and its coactivator CBP, these C9 variants could indirectly affect transcriptional programs critical for cellular responses to stress, immunity, and even neurological functions. [4] Dysregulation of complement activity can contribute to chronic inflammation, a state known to impact CREB/CBP-dependent gene expression in various tissues.
The genetic landscape also includes variants rs2048493 and rs1799807 , affecting the long non-coding RNA LINC01322, the enzyme BCHE, and the extracellular matrix protein VTN. LINC01322 is an lncRNA, a type of RNA molecule that does not code for proteins but instead regulates gene expression by influencing chromatin structure or interacting with other RNA molecules or proteins. BCHE encodes butyrylcholinesterase, an enzyme primarily recognized for its role in hydrolyzing choline esters and metabolizing certain drugs, thereby influencing aspects of the cholinergic system and detoxification processes. [4] VTN, or Vitronectin, is a glycoprotein involved in cell adhesion, migration, and the regulation of both coagulation and complement pathways. Variants likers2048493 and rs1799807 could modify the regulatory potential of LINC01322, alter BCHE enzyme activity, or affect VTN’s structural and functional properties, collectively impacting cellular communication, metabolism, and immune responses. These diverse molecular effects could converge on pathways that regulate CREB binding protein activity, as cholinergic signaling, cell-matrix interactions, and gene expression modulation by lncRNAs all have documented links to CREB/CBP-mediated gene transcription and cellular plasticity.[4]
The variant rs704 is associated with the SARM1 gene, which plays a pivotal role in the molecular pathways governing axon degeneration. SARM1 functions as an enzyme that depletes NAD+, a vital cellular coenzyme, initiating a cascade that leads to the breakdown of axons, the long projections of nerve cells essential for communication. Variations in SARM1, such as rs704 , can influence the gene’s activity or the protein’s susceptibility to activation, thereby affecting the resilience of axons to injury or disease and potentially impacting the progression of neurodegenerative conditions.[4]Axonal health and neuronal survival are closely intertwined with the function of CREB binding protein, which regulates the expression of genes involved in neuroprotection, neuronal plasticity, and cellular repair. Therefore, modifications inSARM1 activity due to rs704 could indirectly alter CREB/CBP signaling, influencing the brain’s ability to maintain neuronal integrity and adapt to challenges. [4]
No information regarding ‘creb binding protein’ is available in the provided context.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs62359722 | INTS6P1 - GCSHP1 | CREB-binding protein measurement protein measurement |
| rs62358361 rs835219 | C9 | atrophic macular degeneration, age-related macular degeneration, wet macular degeneration CREB-binding protein measurement complement component C9 measurement |
| rs2048493 | LINC01322, BCHE | blood protein amount protein CEI measurement CREB-binding protein measurement |
| rs1799807 | BCHE, LINC01322 | protein measurement FEV/FVC ratio level of cholinesterase in blood peak expiratory flow forced expiratory volume |
| rs704 | VTN, SARM1 | blood protein amount heel bone mineral density tumor necrosis factor receptor superfamily member 11B amount low density lipoprotein cholesterol measurement protein measurement |
References
Section titled “References”[1] Agrawal, Abhay, et al. “Transcription Factor c-Rel Enhances C-Reactive Protein Expression by Facilitating the Binding of C/EBPbeta to the Promoter.”Molecular Immunology, vol. 40, no. 6, 2003, pp. 373–380.
[2] Reiner, Alex P., et al. “Polymorphisms of the HNF1A Gene Encoding Hepatocyte Nuclear Factor-1 Alpha Are Associated with C-Reactive Protein.”American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1193–1201.
[3] Ridker, Paul M., et al. “Loci Related to Metabolic-Syndrome Pathways Including LEPR, HNF1A, IL6R, and GCKR Associate with Plasma C-Reactive Protein: The Women’s Genome Health Study.”American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1185–1192.
[4] Benjamin, E. J., et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, vol. 8, 2007.
[5] Vasan, Ramachandran S., et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Medical Genetics, vol. 8, 2007, p. 56.
[6] Hwang, Shih-Jen, et al. “A genome-wide association for kidney function and endocrine-related traits in the NHLBI’s Framingham Heart Study.” BMC Medical Genetics, vol. 8, 2007, p. 53.
[7] Yang, Qiong, et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Medical Genetics, vol. 8, 2007, p. 55.